Is Pluristem Therapeutics (PSTI) Stock a Good Buy?

Pluristen Therapeutics PSTI Stock News

Pluristem Therapeutics Inc. (NASDAQ: PSTI) is screaming for the top in the market this morning, and for good reason. The company announced a landmark collaboration agreement with the largest food producer in Israel. Here’s the scoop: Stop wasting your time! Start finding winning trades in minutes with Trade Ideas! PSTI Announces Landmark Collaboration As mentioned … Read more

Pluristem Therapeutics (PSTI) Stock: Gaining On Clinical Update

Pluristen Therapeutics PSTI Stock News

Pluristem Therapeutics Inc. (NASDAQ: PSTI) is having an incredibly strong start to the trading session this morning, and for good reason. The company provided a clinical update, exciting investors and sending the stock on a run for the top. Today, we’ll talk about: The clinical update; what we’re seeing from PSTI stock as a result; … Read more

Pluristem Therapeutics (PSTI) Stock: Climbing On Regulatory News

Pluristem Therapeutics Inc. (NASDAQ: PSTI) is having an incredibly strong start to the trading session this morning, and for good reason. The comapny announced news from the FDA that opens the door for it to move forward with the continued development of its PLX-PAD. Of course, the news excited investors who are sending the stock … Read more

Pluristem Therapeutics (PSTI) Stock: Headed Up On Clinical Data

Pluristem Therapeutics Inc. (NASDAQ: PSTI) is having an overwhelmingly strong start to the trading session this morning after the company announced results from a multinational Phase II clinical study. Of course, the results proved to be positive, leading to excitement among investors and sending the stock on a run for the top. Today, we’ll talk … Read more

Pluristem Therapeutics (PSTI) Stock: Headed Up With Catalyst Around The Corner

Pluristem Therapeutics Inc. (NASDAQ: PSTI) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company announced that it would be releasing topline results from a Phase II clinical trial in just over a week. Of course, the suspense is leading to excitement among investors, sending the stock … Read more

Pluristem Therapeutics (PSTI) Stock: Headed Up On FDA Clearance

Pluristem Therapeutics Inc. (NASDAQ: PSTI) is having an incredibly strong time in the pre-market hours this morning, and for good reason. The company announced this morning that the United States Food And Drug Administration has cleared its Investigational New Drug application. Today, we’ll talk about: The FDA Clearance; what we’re seeing from PSTI as a … Read more

Pluristem Therapeutics (PSTI) Stock: Gaining Big On FDA News

Pluristem Therapeutics Inc. (NASDAQ: PSTI) is having an overwhelmingly strong day in the market today, and for good reason. The company announced news from the United States Food and Drug Administration, leading to excitement among investors and sending the stock screaming for the top. Today, we’ll talk about the news, what we’re seeing from the … Read more

Pluristem Therapeutics (PSTI) Stock: Falling Hard On Offering

Pluristem Therapeutics Inc. (NASDAQ: PSTI) is having an incredibly rough time in the market this morning, and for good reason. The company announced an offering that is leading to concerns with regard to dilution. Of course, this is leading to fear among investors, sending the stock spiraling toward the bottom and prompting our partners at … Read more

Pluristem Therapeutics (PSTI) Stock: Gaining On Orphan Drug Designation

Pluristem Therapeutics Inc. (NASDAQ: PSTI) is having an incredibly strong start to the trading session in the pre-market hours this morning, and for good reason. The company announced great news that it has received from the FDA, leading to excitement among investors and gains in the value of the stock. Of course, our partners at … Read more

Pluristem Therapeutics (PSTI) Stock: Gaining Big On FDA News

Pluristem Therapeutics Inc. (NASDAQ: PSTI) is off to an incredibly strong start to the trading session this morning after the company announced that the FDA has granted Fast Track Designations to one of their pipeline drugs. As we have grown to expect, the news was overwhelmingly exciting to investors who are pushing the stock toward … Read more